Luis Paz-Ares, MD, PhD

Luis Paz-Ares, MD, PhD, discusses efficacy and safety findings from the phase 2 CARMEN-LC05 trial of tusamitamab ravtansine in patients with nonsquamous non–small cell lung cancer with CEACAM5 expression.

Luis G. Paz-Ares, MD, PhD, discuses the importance of nivolumab plus ipilimumab in the treatment of patients with metastatic non–small cell lung cancer.

Luis Paz-Ares, MD, PhD, Professor of Medicine at Hospital Universitario 12 de Octubre in Madrid, Spain, discusses a subgroup analysis of patients with EGFR-expressing tumors from the SQUIRE trial, a phase III study of gemcitabine–cisplatin plus necitumumab versus gemcitabine–cisplatin alone as first-line treatment for patients with stage IV squamous non-small cell lung cancer (NSCLC).

Dr. Paz-Ares From Seville University Hospital Discusses the Use of Pemetrexed for NSCLC

Dr Paz-Ares from Seville University Hospital Discusses Pemetrexed Clinical Trial